Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urinary markers of malignancy.

F Koenig1, K Jung, D Schnorr

  • 1Department of Urology, Charité Medical School, Humboldt University, Schumannstr. 20-21, 10119, Berlin, Germany. frank.koenig@charite.de

Clinica Chimica Acta; International Journal of Clinical Chemistry
|June 8, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).

Frontiers in pharmacology·2022
Same author

Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak.

Science (New York, N.Y.)·2019
Same author

A proposal for a new PhD level curriculum on quantitative methods for drug development.

Pharmaceutical statistics·2018
Same author

"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?

Clinical pharmacology and therapeutics·2016
Same author

Shade adaptation in cyanobacteria : Further characterization of Anacystis shade phenotype as induced by sublethal concentrations of DCMU-type inhibitors in strong light.

Photosynthesis research·2014
Same author

Cephalometric assessment of craniofacial dysmorphologies in relation with Msx2 mutations in mouse.

Orthodontics & craniofacial research·2014

Transitional cell carcinoma (TCC) recurrence is high despite resection. New urine diagnostic tests are needed for effective screening, follow-up, and treatment selection for bladder cancer.

Area of Science:

  • Urology
  • Oncology
  • Biomarkers

Background:

  • Transitional cell carcinoma (TCC) is a common genitourinary malignancy with high recurrence rates.
  • While many superficial tumors are diagnosed initially, invasive progression or death can occur.
  • Diagnostic urine tests are ideal for TCC screening and follow-up due to ease of sample collection.

Purpose of the Study:

  • To review the current status of diagnostic urine tests for bladder cancer.
  • To discuss the clinical utility of various urinary markers for TCC.
  • To highlight the need for further multi-center studies and prospective trials.

Main Methods:

  • Literature review of diagnostic tests for urinary markers.
  • Discussion of current clinical practices and challenges in TCC management.

Related Experiment Videos

  • Evaluation of existing and potential urinary tumor markers.

    • Main Results:

    • No single urinary marker is routinely used in clinical practice for TCC.
    • Promising markers require further evaluation in multi-center clinical studies.
    • Prospective trials are needed to identify prognostic indicators for disease progression and treatment response.

    Conclusions:

    • New diagnostic urine tests could significantly improve TCC patient management.
    • These tests may help identify patients who will benefit most from specific treatments like cystectomy or bladder-sparing protocols.
    • Further research is essential to validate and implement novel urinary biomarkers in clinical settings.